EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Targeting innate immune memory: a new paradigm for gout treatment

Orsolya I. Gaal, Leo A.B. Joosten, Tania O. Crișan

Exploration of Musculoskeletal Diseases · 2025

DOI: 10.37349/emd.2025.1007103 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Exploration of Musculoskeletal Diseases, 2025. Verfasst von Orsolya I. Gaal und 2 weiteren Autor:innen. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 99 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Gout is a chronic inflammatory arthritis driven by monosodium urate crystal deposition and the NACHT, LRR, and PYD domains-containing protein 3 (NLRP3) inflammasome activation, leading to interleukin-1β (IL-1β)-mediated inflammation. Recent studies reveal that hyperuricemia induces a state of immunological memory in innate immune cells through persistent epigenetic and metabolic reprogramming of monocytes and macrophages. These alterations enhance the responsiveness of innate immune cells, leading to exaggerated inflammatory reactions upon subsequent stimulation. This review synthesizes recent studies that elucidate how metabolic shifts (e.g., increased glycolysis and fumarate accumulation) and epigenetic changes (e.g., altered histone methylation and DNA methylation) reinforce this pathogenic memory. Importantly, these mechanistic insights provide the rationale for emerging therapeutic strategies: IL-1β inhibitors aim to interrupt the central inflammatory axis; metabolic modulators (e.g., metformin, statins) seek to reverse the trained metabolic state; and epigenetic therapies [e.g., histone deacetylase (HDAC) or DNA methyltransferase (DNMT) inhibitors] hold potential to reset dysregulated immune programming. Collectively, this review argues that multi-layered intervention, such as cytokine blockade for acute control, coupled with metabolic or epigenetic remodeling for long-term reprogramming, could yield sustained disease suppression and reduced flare frequency in gout.

Zitieren

APA

Gaal, O. I., Joosten, L. A., & Crișan, T. O. (2025). Targeting innate immune memory: a new paradigm for gout treatment. Exploration of Musculoskeletal Diseases. https://doi.org/10.37349/emd.2025.1007103

Vancouver

Gaal OI, Joosten LA, Crișan TO. Targeting innate immune memory: a new paradigm for gout treatment. Exploration of Musculoskeletal Diseases. 2025. doi:10.37349/emd.2025.1007103

BibTeX
@article{Gaal2025,
  author = {Gaal, Orsolya I. and Joosten, Leo A.B. and Crișan, Tania O.},
  title = {Targeting innate immune memory: a new paradigm for gout treatment},
  journal = {Exploration of Musculoskeletal Diseases},
  year = {2025},
  doi = {10.37349/emd.2025.1007103}
}
Kostenlos starten →